3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
41
Stomach Neoplasms
3
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Pleuropulmonary blastoma
1
Patient Preference
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma
1
Inflammatory Breast Neoplasms
1
Hematologic Neoplasms
1
HER2-positive Breast Cancer
1
HER2 Positive Breast Cancer
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
Sorafenib
52
pembrolizumab
26
Nivolumab
20
Bevacizumab
19
Radiosurgery
17
Doxorubicin
12
atezolizumab
9
Erlotinib Hydrochloride
9
lenvatinib
8
cabozantinib
7
Magnetic Resonance Spectroscopy
7
tremelimumab
6
durvalumab
6
Ramucirumab
6
Radiofrequency Ablation
6
Cisplatin
6
Sunitinib
5
tislelizumab
4
regorafenib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fluorouracil
4
Everolimus
4
Capecitabine
4
nintedanib
3
fluoromisonidazole
3
carotuximab
3
bavituximab
3
Tomography, X-Ray Computed
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Hepatocellular
×
Ado-Trastuzumab Emtansine
×
Clear all
No trials found.